Mccarter Private Wealth Services LLC Sells 15,913 Shares of Edwards Lifesciences Corporation $EW

Mccarter Private Wealth Services LLC decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 37.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,382 shares of the medical research company’s stock after selling 15,913 shares during the period. Edwards Lifesciences accounts for about 1.0% of Mccarter Private Wealth Services LLC’s portfolio, making the stock its 28th biggest position. Mccarter Private Wealth Services LLC’s holdings in Edwards Lifesciences were worth $2,249,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in EW. Washington Trust Advisors Inc. raised its stake in Edwards Lifesciences by 15.6% during the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock worth $10,156,000 after buying an additional 17,625 shares during the period. Atlantic Union Bankshares Corp raised its stake in Edwards Lifesciences by 2,240.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after buying an additional 11,384 shares during the period. Azzad Asset Management Inc. ADV raised its stake in Edwards Lifesciences by 330.5% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company’s stock worth $1,651,000 after buying an additional 16,296 shares during the period. Elo Mutual Pension Insurance Co raised its stake in Edwards Lifesciences by 39.9% during the 3rd quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock worth $6,974,000 after buying an additional 25,562 shares during the period. Finally, Oppenheimer Asset Management Inc. raised its stake in Edwards Lifesciences by 57.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 37,880 shares of the medical research company’s stock worth $2,946,000 after buying an additional 13,820 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of research reports. BTIG Research upped their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research note on Wednesday, April 1st. Barclays reaffirmed an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Finally, Evercore reissued an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $87.59 on Wednesday. The company has a market cap of $50.44 billion, a PE ratio of 46.59, a price-to-earnings-growth ratio of 2.21 and a beta of 0.87. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $89.14. The business has a 50 day moving average price of $81.85 and a 200-day moving average price of $83.02. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,371,239.08. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 95,057 shares of company stock valued at $7,874,217 over the last three months. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.